CTC Pancreatic Adenocarcinoma

• Status: Completed
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Collaborators: Cantonal Hospital of St. Gallen; Kantonsspital Winterthur KSW; Triemli Hospital
• Treatments: Anesthetics; Desflurane; Isoflurane

Criteria

Inclusion Criteria:

• Age 18 to 85

• ASA I-III ( American Society of Anesthesiologists)

• Resectable pancreatic adenocarcinoma

• Primary surgery

• No neoadjuvant therapy

• Written informed consent

Exclusion Criteria:

• Metastatic disease

• Other than primary surgery (recurrence, reconstruction)

• Pre-operative chemotherapy

• Chronic opioid use

• Known hypersensitivity or suspected allergy to propofol, soya or egg proteins

• Known hypersensitivity to volatile anaesthetics (malignant hyperthermia)

• Pregnancy

• Breast feeding

• Enrolment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion